ClinicalTrials.gg

Program

HDAC Class I/IIb Inhibitor HG146

Its studies are mostly in Carcinoma, Adenoid Cystic · Lymphoma · Multiple Myeloma, led by HitGen.

Furthest: phase 2, since Jan 6, 20253 company-led studies, 1 open or runningNext primary completion: Dec 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HitGen31 open or runningphase 2since Jan 6, 2025Sep 29, 2018Dec 31, 2028phase 2 · NCT06781567

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 29, 2018First study: phase 1 study in Multiple MyelomaFirst studyNCT03710915 · 3 enrolled · China
  2. Jul 12, 2021Phase 1 study in LymphomaNCT04977167 · 24 enrolled · China
  3. Jan 6, 2025Phase 2 study in Carcinoma, Adenoid CysticNCT06781567 · 140 planned · China

Ahead

  1. Dec 31, 2028Primary completion: phase 2 study in Carcinoma, Adenoid CysticNCT06781567

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06781567Carcinoma, Adenoid Cystic · China2RecruitingDec 31, 2028140
NCT04977167Lymphoma · China1CompletedJun 13, 202424
NCT03710915Multiple Myeloma · China1TerminatedSep 28, 20223

How it is read

Names in the registry

  • “HG146”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.